NextCure Q3 2023 net loss $14.3M vs $18.9M YoY; cash $118.2M funds into mid-2025

NextCure, Inc.

2023-Q3 EPS reported -$1.73

Cash and securities $118.2M at Sep 30 2023, down $41.7M from Dec 31 2022; expects funding into mid-2025.
Net loss $14.3M for Q3 2023 vs $18.9M for Q3 2022; narrowed loss due to lower R&D and G&A costs.
R&D expenses $11.0M (down from $13.5M); G&A $4.6M (down from $5.7M).
Phase 1b updates for NC410 and NC762, and NC525 Phase 1a update expected by year end 2023.
Selected LNCB74 (B7-H4 ADC) from LegoChem collaboration; presented data on NC605 and NC181.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

NextCure, Inc. reported quarter ended September 30, 2023 results: net income Net loss was $14.3 million for the quarter ended September 30, 2023.

Period: quarter ended September 30, 2023
Net income: Net loss was $14.3 million for the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results

View on SEC.gov

Browse all earnings releases →

NextCure, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-017418

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.